Table 2.

Summary of incidence of hyperkalaemia, hypokalaemia, hypomagnesaemia, and increase of spironolactone dose

	No. (%) of patients		P-value
	RLY5016 30 g/day (n= 55)	Placebo (n= 49)
Serum potassium >5.5 mEq/La	4 (7)	12 (25)	0.015
Serum potassium <4.0 mEq/L	26 (47)	5 (10)	<0.001
Serum potassium <3.5 mEq/L	3 (6)	0 (0)	0.094
Serum magnesium <1.8 mg/dL	13 (24)	1 (2)	0.001
Spironolactone dose increased	50 (91)	36 (74)	0.019

^aAt any study visit.